<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00776113</url>
  </required_header>
  <id_info>
    <org_study_id>021/CARVE-12.5/03</org_study_id>
    <nct_id>NCT00776113</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Carvedilol 12.5mg Tablets Under Fasting Conditions</brief_title>
  <official_title>An Open Label, Balanced, Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover Bioavailability Study on Carvedilol Formulations Comparing Carvedilol 12.5 mg Tablets of Ranbaxy Laboratories With Coreg® 12.5 mg Tablets of Glaxosmithkline in Healthy, Adult, Human Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ranbaxy Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ranbaxy Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to compare the single-dose oral bioavailability of Carvedilol&#xD;
      12.5 mg tablets of Ohm Laboratories with Coreg 12.5 mg tablets in healthy, adult, human&#xD;
      subjects under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was conducted as an open label, balanced, randomized, two-treatment, two-sequence,&#xD;
      two-period, single-dose, crossover, bioavailability study on carvedilol formulation comparing&#xD;
      carvedilol 12.5mg of Ohm Laboratories, Inc. (a subsidiary of Ranbaxy pharmaceuticals Inc,&#xD;
      USA) with Coreg® 12.5mg tablet (containing carvedilol 12.5 mg) of GlaxoSmithKline, USA in&#xD;
      healthy, adult, male, human subjects under fasting condition.&#xD;
&#xD;
      Forty healthy, adult, human subjects who met the inclusion and exclusion criteria as&#xD;
      described in the protocol were enrolled in the study. Thirty-six subjects completed both the&#xD;
      periods of the study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">December 2003</completion_date>
  <primary_completion_date type="Actual">September 2003</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carvedilol 12.5 mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carvedilol 12.5 mg tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol 12.5 mg tablets</intervention_name>
    <description>bioequivalence Carvedilol fasting</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be in the' age range of 18-45 years.&#xD;
&#xD;
          -  Be neither overweight nor underweight for his/her height as per the Life Insurance&#xD;
             Corporation of lndia height/weight chart for non-medical cases.&#xD;
&#xD;
          -  Have voluntarily given written informed consent to participate in this study.&#xD;
&#xD;
          -  Be of normal health as determined by medical history and physical examination of the&#xD;
             subjects performed within :1.4 days prior to the commencement of the study.&#xD;
&#xD;
        If female and:&#xD;
&#xD;
          -  Of childbearing potential, is practicing an acceptable method of birth control for the&#xD;
             duration of the study as judged by the investigator(s), such as condoms, foams,&#xD;
             jellies, diaphragm, intrauterine device ([UD), or abstinence; or Is postmenopausal for&#xD;
             at least 1 year; or&#xD;
&#xD;
          -  Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or&#xD;
             hysterectomy).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allergy to 13-adrenoceptor antagonists especially carvedilol.&#xD;
&#xD;
          -  Any evidence of organ dysfunction or any clinically significant deviation from the&#xD;
             normal, in physical or clinical determinations.&#xD;
&#xD;
          -  Presence of disease markers of HIV 1 and 2, Hepatitis B and C viruses or syphilis&#xD;
             infection.&#xD;
&#xD;
          -  Female volunteers demonstrating a positive pregnancy test.&#xD;
&#xD;
          -  Female volunteers who are currently breastfeeding.&#xD;
&#xD;
          -  Presence of values which are significantly different from normal reference ranges (as&#xD;
             defined in Appendix 5) and/or judged clinically significant for haemoglobin, total&#xD;
             white blood cells count, differential WBC count or platelet count.&#xD;
&#xD;
          -  Positive for urinary screen testing of drugs of abuse (opiates And cannabinoids)&#xD;
&#xD;
          -  Presence of values which are significantly different from normal reference ranges (as&#xD;
             defined in Appendix 5) and/or judged clinically significant for serum creatinine,&#xD;
             blood urea nitrogen, serum aspartate aminotransferase (AST), serum alanine&#xD;
             aminotransferase (ALT), serum alkaline phosphatase, serum bilirubin, plasma glucose or&#xD;
             serum cholesterol.&#xD;
&#xD;
          -  Clinically abnormal chemical and microscopic examination of urine defined as presence&#xD;
             of RBC, WBC (&gt;4/HPF), epithelial cells (&gt;4/HPF), glucose (positive) or protein&#xD;
             (positive).&#xD;
&#xD;
          -  Clinically abnormal ECG or Chest X-ray.&#xD;
&#xD;
          -  History of serious gastrointestinal, hepatic, renal, cardiovascular, pulmonary,&#xD;
             neurological or haematological disease, diabetes, glaucoma, bronchial asthma, fainting&#xD;
             or syncope.&#xD;
&#xD;
          -  History of any psychiatric illness which may impair the ability to provide written&#xD;
             informed consent.&#xD;
&#xD;
          -  Regular smokers who smoke more than 10 cigarettes daily or have difficulty abstaining&#xD;
             from smoking for the duration of each study period.&#xD;
&#xD;
          -  History of drug dependence or excessive alcohol intake on Habitual basis of more than&#xD;
             2 units of alcoholic beverages per day (1 Unit equivalent to half pint of beer or !&#xD;
             glass of wine or I measure of spirit) or have difficulty_ in abstaininq for the&#xD;
             duration of each study period.&#xD;
&#xD;
          -  Use of any enzyme modifying drugs within 30 days prior to Day 1 of this study.&#xD;
&#xD;
          -  Participation in any clinical trial within 12 weeks preceding Day 1 of this study.&#xD;
&#xD;
          -  A haemoglobin concentration of less than 7 % of lower limit of reference range e.g. 13&#xD;
             gm % for reference range of 1448 gm at screening.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://clinicalstudies.ranbaxy.com</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/about.cfm</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>October 16, 2008</study_first_submitted>
  <study_first_submitted_qc>October 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2008</study_first_posted>
  <last_update_submitted>October 17, 2008</last_update_submitted>
  <last_update_submitted_qc>October 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Tausif Monif</name_title>
    <organization>Ranbaxy Research laboratories</organization>
  </responsible_party>
  <keyword>Bioequivalence Carvedilol fasting</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

